Marita Ziepert

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford et al. · Nature Medicine · 2018 · 2K citations · Full text

Medicine, Hematology, Oncology +12

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Norbert Schmitz, Lorenz Trümper, Marita Ziepert et al. · Blood · 2010 · 592 citations · Full text

Medicine, Hematology, Oncology +15

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20⁺B-Cell Lymphoma in the Rituximab Era

Marita Ziepert, Dirk Hasenclever, Evelyn Kuhnt et al. · Journal of Clinical Oncology · 2010 · 585 citations · Full text

Medicine, Immunology, Oncology +13

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Heike Horn, Marita Ziepert, Claudia Becher et al. · Blood · 2013 · 544 citations

Medicine, Hematology, Oncology +11